Grail (GRAL) said Wednesday it has seen better cancer detection results from an analysis of the first 25,578 participants in its Pathfinder 2 study compared with the previous Pathfinder study.
The Pathfinder 2 study was launched in 2021 to assess the safety and performance of the Galleri cancer detection test when added to standard of care in 35,878 adults with more than 50 years of age and with no clinical suspicion of cancer, Grail said.
In Pathfinder 2, adding Galleri to standard of care tests showed "substantially greater additional cancer detection" than in the prior study, the company said.
The results from the latest study also indicated a "substantially higher" positive predictive value than that seen in the previous study, Grail said.
The company also said "no serious safety concerns" were seen in the Pathfinder 2 study.
Grail shares were up more than 4% in recent early trading.
Price: 43.97, Change: +1.92, Percent Change: +4.57
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。